Drug therapy for atrial fibrillation: where do we go from here?
- 1 November 2005
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 4 (11) , 899-910
- https://doi.org/10.1038/nrd1876
Abstract
Atrial fibrillation, the most common cardiac arrhythmia requiring medical attention, has effects that range from mild symptoms to devastating stroke. Although treatments have evolved since the foxglove plant (later identified as containing digitalis) was first administered to slow the heart rate, satisfactory drug therapy has not been developed. In this review we describe present-day medical options and developments of future therapies to treat atrial fibrillation and maintain normal sinus rhythm.Keywords
This publication has 100 references indexed in Scilit:
- Atrial Fibrillation in KCNE1-Null MiceCirculation Research, 2005
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- A Kir2.1 gain-of-function mutation underlies familial atrial fibrillationBiochemical and Biophysical Research Communications, 2005
- Drug-Induced Prolongation of the QT IntervalNew England Journal of Medicine, 2004
- The statin warsThe Lancet, 2003
- Missense Mutations in the Rod Domain of the Lamin A/C Gene as Causes of Dilated Cardiomyopathy and Conduction-System DiseaseNew England Journal of Medicine, 1999
- Left atrial diameter in nonvalvular atrial fibrillation: An echocardiographic studyAmerican Heart Journal, 1999
- Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial InfarctionNew England Journal of Medicine, 1989
- Tachycardia-induced cardiomyopathy: A reversible form of left ventricular dysfunctionThe American Journal of Cardiology, 1986
- Experimental studies on auricular flutter and auricular fibrillationAmerican Heart Journal, 1948